On March 7, 2022 Shuwen Biotech, an integrated in vitro diagnostic company with focuses on breast cancer and reproductive health, reported that it has entered into a distribution agreement with Devyser Diagnostics AB, a Stockholm, Sweden-based diagnostic company, to market and support Devyser BRCA NGS and other oncology kits in China (Press release, Shuwen Biotech, MAR 7, 2022, View Source [SID1234609735]). Under the terms of the agreement, Shuwen will distribute the Devyser kits in China and also offer testing and NGS data analysis services with the Devyser kits in its CAP-accredited clinical labs in China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Devyser BRCA NGS is a CE-certified next-generation sequencing (NGS) library prep kit for fast and complete characterization of BRCA1 and BRCA2. The kit employs a unique single-tube approach which simplifies the workflow, reduces hands-on time and minimizes the risk of sample mix-up and contamination. The kit provides full and uniform coverage of BRCA1 and BRCA2, covering all exons and exon/intron junctions, and also allows downstream CNV analysis, thus enabling detection of point mutations, indels, and large rearrangements based on a single-tube reaction.

"We are pleased to add Devyser BRCA NGS and other oncology kits to our portfolio of cancer testing products. They further strengthen our leading position in breast cancer product and service offerings in China, which already feature MammaTyper and EndoPredict, and other tests for precision medicine in breast cancer," commented Jay Z. Zhang, Chairman and CEO of Shuwen Biotech.